BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Price, Financials & Summary

Price chart

Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6

Key dataNov 6, 2026

Open$7.81

From 52W high−30.78%

Volume5.21M

Market cap$1.98B

P/E (TTM)—

P/S (TTM)2.1x

Div yield—

Key dataNov 6, 2026

Open

$7.81

From 52W high

−30.78%

Volume

5.21M

Market cap

$1.98B

ValuationView details →

P/E (Fwd)

11.6x

EV/EBITDA

−8.5x

P/E (TTM)

—

RSI (14)

37.6

MomentumView details →

1D Return

+0.79%

YTD Return

−4.10%

SummaryUpdated Sep 1, 2026

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company founded in 1986 and headquartered in Durham, North Carolina. The company went public in 1994 and has evolved from a drug discovery platform focused on structure-based drug design into a commercial-stage biopharmaceutical company. BioCryst specializes in developing oral, small-molecule medicines for rare diseases, with its flagship product ORLADEYO becoming a significant commercial success in treating hereditary angioedema. The company has transitioned from a research-focused entity burning substantial cash to approaching profitability, driven primarily by the strong commercial performance of its lead drug.

Ask drillr about BIOCRYST PHARMACEUTICALS INC →

ValuationView details →

P/E (Fwd)

11.6x

P/E (TTM)

—

EV/EBITDA

−8.5x

EV/Sales

2.5x

P/S (TTM)

2.1x

P/B (TTM)

−5.0x

ProfitabilityView details →

Gross Margin

25.28%

Net Margin

−37.41%

EBITDA Margin

−29.65%

ROE (TTM)

90.51%

ROA (TTM)

−60.85%

Asset Turnover

1.67x

GrowthView details →

Revenue YoY

+60.30%

EPS YoY

—

FCF YoY

+630.49%

Revenue CAGR 3Y

+47.82%

EPS CAGR 3Y

+393.02%

EBITDA YoY

—

MomentumView details →

1D Return

+0.79%

YTD Return

−4.10%

1Y Return

+5.50%

RSI (14)

37.6

vs 50D SMA

−11.58%

vs 200D SMA

−14.79%

Capital & dividendView details →

Debt/Equity

−2.08x

Current Ratio

2.71x

Quick Ratio

2.64x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.14

EPS Surprise

52.41%

Beats (12Q)

8/12

Next Q EPS Est

$0.11

Avg Surprise (4Q)

374.24%

Rev Surprise

8.83%

Financials snapshotView financials →

Revenue (TTM)

961.51M

Net Income (TTM)

−359.66M

Op. CF (TTM)

351.23M

Next earningsFeb 25, 2027 →

Latest newsMore news →

BIOCRYST PHARMACEUTICALS INC reported quarterly earnings of $0.14 per share, compared with $0.06 per share a year earlier.3d ago

BioCryst Pharmaceuticals reported third-quarter 2026 total net revenue of $180.3 million, including $174.8 million from ORLADEYO, operating profit of $53.3 million and non-GAAP operating profit of $86.5 million.4d ago

Similar companies

Mabpharm Limited02181.HK First Tracks Biotherapeutics IncTRAX Harmony Biosciences Holdings, Inc.HRMY Veracyte, Inc.VCYT Trevi Therapeutics, Inc.TRVI Replimune Group, Inc.REPL Find similar companies →

Latest newsMore news →

BIOCRYST PHARMACEUTICALS INC reported quarterly earnings of $0.14 per share, compared with $0.06 per share a year earlier.3d ago BioCryst Pharmaceuticals reported third-quarter 2026 total net revenue of $180.3 million, including $174.8 million from ORLADEYO, operating profit of $53.3 million and non-GAAP operating profit of $86.5 million.4d ago BioCryst Pharmaceuticals announced that it will report its third-quarter 2026 financial results on November 4, 2026.17d ago